Welcome to LookChem.com Sign In|Join Free
  • or
N-(4-CHLOROPHENYL)SULFONYL(4-IODO)ANILINE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

346718-87-4

Post Buying Request

346718-87-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

346718-87-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 346718-87-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,6,7,1 and 8 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 346718-87:
(8*3)+(7*4)+(6*6)+(5*7)+(4*1)+(3*8)+(2*8)+(1*7)=174
174 % 10 = 4
So 346718-87-4 is a valid CAS Registry Number.

346718-87-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(4-CHLOROPHENYL)SULFONYL(4-IODO)ANILINE

1.2 Other means of identification

Product number -
Other names 4-Chlor-benzolsulfonsaeure-(4-chlor-N-methyl-anilid)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:346718-87-4 SDS

346718-87-4Relevant academic research and scientific papers

5-LIPOXYGENASE INHIBITORS

-

Page/Page column 34, (2009/12/28)

The use of compounds of the formula (I) Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2 (I) where Y is selected from O or S; R1 is H, a salt or readily hydrolysable s

HDAC INHIBITORS

-

Page/Page column 33, (2008/12/06)

The use of compounds of the formula (I): Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2 where Y is selected from O or S; R1 is H, a salt or readily hydrolysable substituent; R2 is selected from H or CH3, CH2F, CF2H or CF3; R3 and R4 are selected independently from H, C1-4 alkyl or alkenyl, CF3, CH2F, CF2H and F, with the proviso that if either R3 or R4 is H, then the other is not H; L1 is a linker group; L2 is a linker group comprising an optionally substituted or unsubstituted unsaturated branched or straight chain alkyl group; Ar1 is an optionally substituted or unsubstituted aryl or heterocyclic group; and Ar2 is an optionally substituted or unsubstituted aryl or heterocyclic group, in the treatment of HDAC mediated diseases or diseases provide improved therapies due to the potent inhibition of HDAC and long duration of activity in vivo after oral administration. They are potential useful in diseases in which HDAC has been implicated, e.g. psoriasis, cancer, Alzheimer's disease, Huntington's disease and HIV.

Polymer-assisted, multi-step solution phase synthesis and biological screening of histone deacetylase inhibitors

Bapna, Akanksha,Vickerstaffe, Emma,Warrington, Brian H.,Ladlow, Mark,Fan, Tai-Ping D.,Ley, Steven V.

, p. 611 - 620 (2007/10/03)

The polymer-assisted solution phase synthesis (PASP) of an array of histone deacetylase (HDAc) inhibitors is described. HDAc inhibitors have considerable potential as new anti-proliferative agents. Selected compounds were shown to inhibit both human endothelial cell proliferation, and the formation of tubules (neovascularisation) in an in vitro model of angiogenesis.

Design and synthesis of a novel class of histone deacetylase inhibitors.

Lavoie,Bouchain,Frechette,Woo,Abou-Khalil,Leit,Fournel,Yan,Trachy-Bourget,Beaulieu,Li,Besterman,Delorme

, p. 2847 - 2850 (2007/10/03)

Histone deacetylase inhibitors (HDACs) have emerged as a novel class of antiproliferative agents. Utilizing structure-based design, the synthesis of a series of sulfonamide hydroxamic acids is described. Further optimization of this series by substitution of the terminal aromatic ring yielded HDAC inhibitors with good in vitro and in vivo activities.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 346718-87-4